🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the fight against superbug strains of the infection, according to health experts.

A Global Health Concern

Cases of gonorrhoea are increasing worldwide, with estimates suggesting more than 82 million new cases each year. Especially elevated rates are reported in Africa and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the reality of growing infection rates, the spread of superbugs and the highly restricted therapeutic options at this time.”

Health officials are deeply concerned about the surge in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Recent surveillance showed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Therapies Gain Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers anticipate that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

This new treatment stemmed from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval represents a significant shift in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

According to data detailed in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This puts it on an equal footing with the typical regimen, which combines two antibiotics. The research enrolled hundreds of patients from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the rights to make available and distribute the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have shared positive views. Having a one-pill regimen like this is hailed as a "critical tool" for managing the epidemic. This is considered essential to reduce the burden of the disease for people and to stop the proliferation of untreatable gonorrhoea around the world.